Celastrol functions as an emerging manager of lipid metabolism : Mechanism and therapeutic potential
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Lipid metabolism disorders are pivotal in the development of various lipid-related diseases, such as obesity, atherosclerosis, non-alcoholic fatty liver disease, type 2 diabetes, and cancer. Celastrol, a bioactive compound extracted from the Chinese herb Tripterygium wilfordii Hook F, has recently demonstrated potent lipid-regulating abilities and promising therapeutic effects for lipid-related diseases. There is substantial evidence indicating that celastrol can ameliorate lipid metabolism disorders by regulating lipid profiles and related metabolic processes, including lipid synthesis, catabolism, absorption, transport, and peroxidation. Even wild-type mice show augmented lipid metabolism after treatment with celastrol. This review aims to provide an overview of recent advancements in the lipid-regulating properties of celastrol, as well as to elucidate its underlying molecular mechanisms. Besides, potential strategies for targeted drug delivery and combination therapy are proposed to enhance the lipid-regulating effects of celastrol and avoid the limitations of its clinical application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 164(2023) vom: 15. Aug., Seite 114981 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gu, Jia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Celastrol |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 13.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2023.114981 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357876008 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357876008 | ||
| 003 | DE-627 | ||
| 005 | 20231226073532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2023.114981 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357876008 | ||
| 035 | |a (NLM)37285754 | ||
| 035 | |a (PII)S0753-3322(23)00771-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gu, Jia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Celastrol functions as an emerging manager of lipid metabolism |b Mechanism and therapeutic potential |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Lipid metabolism disorders are pivotal in the development of various lipid-related diseases, such as obesity, atherosclerosis, non-alcoholic fatty liver disease, type 2 diabetes, and cancer. Celastrol, a bioactive compound extracted from the Chinese herb Tripterygium wilfordii Hook F, has recently demonstrated potent lipid-regulating abilities and promising therapeutic effects for lipid-related diseases. There is substantial evidence indicating that celastrol can ameliorate lipid metabolism disorders by regulating lipid profiles and related metabolic processes, including lipid synthesis, catabolism, absorption, transport, and peroxidation. Even wild-type mice show augmented lipid metabolism after treatment with celastrol. This review aims to provide an overview of recent advancements in the lipid-regulating properties of celastrol, as well as to elucidate its underlying molecular mechanisms. Besides, potential strategies for targeted drug delivery and combination therapy are proposed to enhance the lipid-regulating effects of celastrol and avoid the limitations of its clinical application | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Celastrol | |
| 650 | 4 | |a Disorders | |
| 650 | 4 | |a Lipid metabolism | |
| 650 | 4 | |a Lipid-related diseases | |
| 650 | 7 | |a celastrol |2 NLM | |
| 650 | 7 | |a L8GG98663L |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Pentacyclic Triterpenes |2 NLM | |
| 650 | 7 | |a Triterpenes |2 NLM | |
| 700 | 1 | |a Shi, Ya-Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Neng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hong-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chan-Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Li |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 164(2023) vom: 15. Aug., Seite 114981 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2023 |g day:15 |g month:08 |g pages:114981 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2023.114981 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2023 |b 15 |c 08 |h 114981 | ||